Skip to main content
Premium Trial:

Request an Annual Quote

Five RNAi-Related Patent Applications Published by the US Patent Office: Sep 10, 2004


Title: Polycyclic Sugar Surrogate-Containing Oligomeric Compounds and Compositions for Use in Gene Modulation. Number: 20040171570. Filed: Nov. 4, 2003. Lead Inventor: Charles Allerson, Isis Pharmaceuticals.

The patent application, its abstract states, covers “compositions comprising first and second oligomers … wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer; at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid; and at least one of the first or second oligomers includes a modification comprising a polycyclic sugar surrogate. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex, wherein at least one nucleoside of the oligomer has a polycyclic sugar surrogate modification.”

Title: Antisense Oligonucleotide Modulation of Human Serine/Threonine Protein Phosphatase Gene Expression. Number: 20040171564. Filed: July 23, 2003. Lead Inventor: Richard Honkanen, University of South Alabama.

“Oligonucleotides are provided which are targeted to nucleic acids encoding human serine/threonine protein phosphatases and which are capable of inhibiting protein phosphatase expression,” the patent application’s abstract states. “Methods of inhibiting the expression of human protein serine/threonine phosphatases using oligonucleotides of the invention are also provided, [as are] methods of preventing or inhibiting hyperproliferation of cells and methods of treating abnormal conditions.”

Title: Methods for Directing DNA Methylation in Mammalian Cells Using Homologous Short Double-Stranded RNAs. Number: 20040171118. Filed: Feb. 12, 2004. Lead Inventor: John Rossi, City of Hope.

“The invention provides methods for methylating a gene of interest in a cell,” the patent application’s abstract states. “The methods include exposing a mammalian cell to an siRNA molecule which is specific for a gene of interest in the cell. The methods also include introducing into the cell DNA sequences encoding a sense strand and an antisense strand of an siRNA which is specific for the gene of interest,” it adds.

Title: Preparations and Use of Single-Stranded Transcription Substrates for Synthesis of Transcription Products Corresponding to Target Sequences. Number: 20040171041. Filed: Nov. 21, 2003. Lead Inventor: Gary Dahl, Epicenter Technologies.

“The … invention provides methods, compositions, and kits for using an RNA polymerase for making transcription products corresponding to a target sequence by obtaining single-stranded DNA transcription substrates that comprise a single-stranded promoter that is operably joined to a single-stranded target sequence,” the patent application’s abstract states. “The invention has broad applicability for research, diagnostic and therapeutic applications, such as preparing cDNA corresponding to full-length mRNA, making sense or anti-sense probes, ... or making RNA for use in RNAi.”

Title: Antivirus RNA. Number: 20040170963. Filed: Dec. 3, 2003. Lead Inventor: Ih-Jen Su, National Cheng-Kung University.

According to the patent application’s abstract, the invention comprises “an RNA molecule for inhibiting expression of a gene of a virus, [as well as] a DNA vector encoding the RNA molecule, … a pharmaceutical composition containing the RNA molecule or vector and a pharmaceutically acceptable carrier, [and] methods for inhibiting expression of a gene of a virus, replication of the virus, and infection with the virus.”

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.